Answers are grounded in this paper and cite their sources.
A cornerstone of autologous cell therapy for Duchenne muscular dystrophy is the engineering of suitable cells to express dystrophin in a stable fashion upon differentiation to muscle fibers. Most viral transduction methods are typically restricted to the expression of truncated recombinant dystrophin derivatives and by the risk of insertional mutagenesis, while non-viral vectors often suffer from inefficient transfer, expression and/or silencing.
No takes yet. Share an insight, caveat, or question.
Zwieten et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: